Comparative Pharmacology
Head-to-head clinical analysis: NORDETTE 28 versus NORINYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORDETTE 28 versus NORINYL.
NORDETTE-28 vs NORINYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined estrogen-progestin oral contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial lining.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) provides contraception by inhibiting gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
One tablet orally once daily for 28 consecutive days.
One tablet (norethindrone 1 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 placebo tablets. For first cycle, start on first Sunday after menstruation begins or on day 1 of menstrual cycle.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (mean 17 hours); Levonorgestrel: 11-45 hours (mean 24 hours); clinical context: steady-state reached after 5-7 days.
Terminal half-life: norethindrone 7-8 hours, ethinyl estradiol 13-27 hours; clinical context: steady-state achieved in 3-5 half-lives
Renal: ~50% as metabolites, ~20% unchanged; Fecal: ~30% as metabolites; Biliary: minimal.
Renal: ~60% as metabolites, biliary/fecal: ~40% as glucuronide conjugates
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive